Current Research Studies
Cancer – SC-4017: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Condition or Therapy:
cancer, medullary thyroid cancer, infantile myofibromatosis, infantile fibrosarcoma, papillary thyroid cancer, soft tissue sarcoma, LOXO-292 therapy
Category:
Cancer and Blood Disorders
Study Number: SC-4017
What is the goal of this study?
Researchers want to determine safety of LOXO-292 and overall response rate to LOXO-292
Who can join the study?
This study may be a good fit for children and young adults who:
- Are between 6 months to 21 years old, and
- Have advanced or metastatic solid or primary CNS tumor which has failed standard of care therapies
- Have evidence of an activating RET gene alteration in the tumor and/ or blood
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.
Study Location(s):
Seattle Children's Main Hospital Campus
Principal Investigator:
Dr. Katie Albert
Research Center: Center for Clinical and Translational Research
